AML1-ETO translocation is usually accompanied by overexpression of mutant C-Kit, a tyrosine kinase, which contributes to uncontrolled proliferation of premature blood cells leading to relapse and poor prognosis.     ///    Esculetin decreases the expression of AML1-ETO at both protein and transcript level within 24 hours of treatment.     ///    Esculetin Downregulates the Expression of AML1-ETO and C-Kit in Kasumi-1 Cell Line by Decreasing Half-Life of mRNA..     ///    Half-life of AML1-ETO mRNA was reduced from 7 hours to 1.5 hours.     ///    Esculetin also perturbed the expression of ectopically expressed AML1-ETO in U937 cells.     ///     One of the most frequent genetic aberrations in acute myeloid leukemia (AML) is chromosomal translocation between AML1/RUNX1 on chromosome 21 and ETO gene on chromosome 8 resulting in the expression of chimeric oncogene AML1-ETO.     ///    "The decreased expression of AML1-ETO chimeric gene was associated with increased expression of LAT1 and RUNX3 genes, targets of AML1. "